3D Medicines, Inc. (1244) AI Stock Analysis

• Market Cap: HK$1.06B
• Dividend Yield: N/A
• Average Volume (3M): 240.72K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.74
• Revenue Growth: -31.34%
• EPS Growth: 67.95%
• Country: HK
• Employees: 191
• Sector: Healthcare
• Sector Strength: 47
• Industry: Biotechnology
• EPS (TTM): -0.81
• Shares Outstanding: 258,177,000
• 10 Day Avg. Volume: 291,000
• 30 Day Avg. Volume: 240,716
• PEG Ratio: -0.11
• Price to Book (P/B): 1.17
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -4.08
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 50 Neutral
• Price Target: HK$4.00 ▼(-2.68%Downside)

The overall stock score is primarily influenced by the strong revenue growth and positive technical indicators. However, significant profitability challenges and unattractive valuation metrics weigh down the overall score. The lack of earnings call and corporate event data prevents a comprehensive assessment.

3D Medicines, Inc. Business Overview & Revenue Model

Company Description

3D Medicines Inc., a biopharmaceutical company, researches, develops, and commercializes oncology products and drug candidates for the treatment of patients with various cancers in Mainland China. It offers Envafolimab, a PD-L1 antibody in the form of subcutaneous injection for the treatment of previously treated microsatellite instability-high (MSI-H)/mismatch repair deficient(dMMR) advanced solid tumors. The company's products in development pipeline include 3D189 for multi-indication tumor and is in phase III clinical trial; 3D229 (GAS6/AXL) for non-small cell lung cancer, ovarian cancer, and kidney cancer and is in phase III clinical trial; 3D1001 for the treatment of postoperative dental pain and tumor pain which is in phase II trial; 3D1002 for oncology pain and is in phase II trial; and 3D185, which is in phase I clinical trial for the treatment of locally advanced or metastatic solid tumors, as well as other products, such as 3D197 for multi-indication tumor immunotherapy, 3D011 for advanced malignant solid tumor, and 3D057 for multiple indications tumors. 3D Medcines Inc. was founded in 2014 and is headquartered in Qingdao, China.

How the Company Makes Money

3D Medicines, Inc. generates revenue primarily through the sale of its proprietary oncology therapies. The company may also engage in strategic partnerships and collaborations with other biotechnology firms, pharmaceutical companies, and research institutions to develop and commercialize new drugs. Additionally, 3D Medicines might receive milestone payments and royalties from licensing agreements with other entities that utilize its technology or products. Another potential revenue stream could be government or private funding for research and development in the field of oncology.

3D Medicines, Inc. Financial Statement Overview

Summary

The company exhibits strong revenue growth, but persistent losses and operational inefficiencies are significant concerns. The balance sheet shows improvement with a better cash position, but cash flow challenges persist with negative operating and free cash flows.

Income Statement

The company shows significant revenue growth from 2020 to 2024, with a strong increase in total revenue. However, the net income remains negative, indicating persistent losses. Gross profit margin is high, but negative EBIT and EBITDA margins highlight operational inefficiencies.

Balance Sheet

The balance sheet shows a strong cash position with substantial cash equivalents and short-term investments. However, the company has a negative equity position until 2022, which improved in later years. The debt-to-equity ratio is concerning due to high leverage in earlier years, but it has improved recently.

Cash Flow

Operating cash flow has been negative, showing challenges in generating cash from core operations. Free cash flow is consistently negative, reflecting high capital expenditures and operational challenges. Financing cash flow is positive, indicating reliance on external funding.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
445.65M	634.95M	567.39M	60.26M	0.00
	Gross Profit
371.74M	524.01M	525.18M	55.98M	0.00
	EBITDA
-226.95M	-529.23M	-1.03B	-1.45B	-303.35M
	Net Income
-182.66M	-524.70M	-1.02B	-1.43B	-635.38M
Balance Sheet		Total Assets
1.22B	1.43B	1.33B	1.06B	496.22M
	Cash, Cash Equivalents and Short-Term Investments
840.98M	996.58M	942.03M	824.48M	414.26M
	Total Debt
237.62M	282.43M	175.70M	58.74M	20.37M
	Total Liabilities
512.54M	558.20M	436.65M	3.33B	1.77B
	Stockholders Equity
785.06M	936.74M	943.00M	-2.24B	-1.27B
Cash Flow		Free Cash Flow
-255.94M	-150.74M	-332.76M	-433.46M	-289.48M
	Operating Cash Flow
-210.58M	-144.41M	-278.78M	-377.08M	-278.33M
	Investing Cash Flow
17.95M	-187.58M	-242.11M	-98.87M	-20.48M
	Financing Cash Flow
-33.92M	304.51M	408.41M	840.08M	607.39M

3D Medicines, Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4.11
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1244, the sentiment is Positive. The current price of 4.11 is below the 20-day moving average (MA) of 4.17, above the 50-day MA of 3.77, and above the 200-day MA of 3.12, indicating a bullish trend. The MACD of 0.10 indicates Positive momentum. The RSI at 58.98 is Neutral, neither overbought nor oversold. The STOCH value of 57.02 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1244.

3D Medicines, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.34B	0.29	-60.38%	2.38%	17.46%	1.71%
1244	50 Neutral	HK$1.06B	―	-21.22%	―	-31.34%	67.95%
7SS		€135.52M	―	-17.41%	―	―	―
67N0		€149.05M	―	-4.30%	―	―	―
1875	68 Neutral	HK$1.48B	36.94	4.92%	―	38.48%	―
2126	54 Neutral	HK$1.07B	―	-41.34%	―	-10.78%	24.88%
6628	47 Neutral	HK$610.93M	―	-32.59%	―	-79.65%	37.50%

3D Medicines, Inc. Corporate Events

3D Medicines Inc. Announces Board Changes with New Non-Executive Director Appointment

3D Medicines Inc. announced a change in its board of directors, with Mr. Zhu Pai retiring as a non-executive director to focus on other engagements. The board expressed gratitude for his contributions. Following his retirement, the company proposes appointing Mr. Zhu Jinqiao, who has extensive experience in investment and entrepreneurship consulting, as the new non-executive director. This transition may influence the company’s strategic direction, given Mr. Zhu Jinqiao’s notable background and achievements in the healthcare investment sector.

3D Medicines Inc. Announces Annual General Meeting to Discuss Key Resolutions

3D Medicines Inc. has announced its upcoming annual general meeting scheduled for June 30, 2025, in Beijing, where shareholders will consider various resolutions, including the adoption of the 2024 financial statements and the election and re-election of directors. The meeting will also address the re-appointment of the company’s auditor and authorize the board to manage director remuneration and share allotments, indicating a focus on strengthening governance and operational oversight.

3D Medicines Announces Board Composition and Governance Structure

3D Medicines, Inc. has announced the composition of its board of directors and their roles within the company. The board consists of executive, non-executive, and independent non-executive directors, with Dr. Gong Zhaolong serving as the executive director. The board has established three committees: Audit, Remuneration, and Nomination, each chaired and populated by various board members. This announcement is significant as it outlines the governance structure of the company, which is crucial for stakeholders to understand the leadership and decision-making processes within 3D Medicines.

3D Medicines Inc. Forms Nomination Committee for Enhanced Governance

3D Medicines Inc. has established a Nomination Committee as part of its corporate governance structure. This committee, formed by the board of directors, is tasked with overseeing the nomination of directors and ensuring that the board comprises individuals with the necessary skills and independence. The establishment of this committee is aligned with the company’s recent listing on the Hong Kong Stock Exchange and reflects its commitment to maintaining robust governance practices.

3D Medicines Inc. Reports 2024 Financial Results Amid Market Challenges

3D Medicines Inc. announced its audited financial results for the year ended December 31, 2024, highlighting a 29.8% decrease in revenue to RMB445.6 million due to intense market competition. Despite this, the company saw a 15.9% increase in sales in the second half of the year compared to the first half, indicating a positive sales trend. The company’s gross profit decreased by 30.2% to RMB409.1 million, with a slight decline in gross profit margin due to increased sales-related taxes and product quality costs. Research and development expenses significantly decreased by 57.5%, attributed to reductions in third-party contracting expenses, employee benefits, and costs associated with in-licensed drug candidates.